Aveo is introducing Fotivda (tivozanib), following the Food and Drug Administration's approval on March 10, 2020.
Fotivda is a treatment for adults with relapsed or refractory advanced renal cell carcinoma following two or more prior systemic therapies. The medication is an oral, next-generation vascular endothelial growth factor tyrosine kinase inhibitor.
“We are thrilled to begin bringing Fotivda to patients battling relapsed or refractory kidney cancer,” said Michael Bailey, Aveo president and CEO. “With its differentiated tolerability and efficacy profile, Fotivda has the potential to serve as a meaningful, evidence-based treatment option for the population of patients who have previously received two prior lines of systemic therapy.”
“We are keenly focused on ensuring that Fotivda is available to as many appropriate patients as possible,” said Mike Ferraresso, chief commercial officer of Aveo. “As part of this effort and our commitment to the RCC community, we have put in place an assistance program, AVEO ACE, which we believe will optimize patient access and help patients navigate their treatment journey. With the early FDA approval, the team has worked hard to make Fotivda available to patients as quickly as possible through our distribution partners and we believe we are well positioned for the successful launch of Fotivda.”
Fotivda is available through a limited distribution network comprised of specialty pharmacies (Biologics & Onco360) and specialty distributors: ASD Healthcare, Oncology Supply, McKesson Plasma and Biologics, McKesson Specialty and Cardinal Specialty.